Jean F. Holloway Sells 8,070 Shares of Artivion, Inc. (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean F. Holloway sold 8,070 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Artivion Trading Down 1.7 %

NYSE AORT opened at $28.99 on Friday. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -1,449.25 and a beta of 1.75. Artivion, Inc. has a twelve month low of $16.48 and a twelve month high of $30.45. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. The business’s fifty day moving average is $27.70 and its 200 day moving average is $26.20.

Analysts Set New Price Targets

AORT has been the subject of several recent analyst reports. Stifel Nicolaus upped their target price on Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Friday, September 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 price objective on shares of Artivion in a research note on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $34.00 target price on shares of Artivion in a research note on Monday, December 9th. Finally, Oppenheimer increased their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a report on Friday, November 8th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Artivion has an average rating of “Buy” and a consensus target price of $31.80.

Institutional Trading of Artivion

A number of hedge funds have recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its stake in shares of Artivion by 3.2% in the second quarter. The Manufacturers Life Insurance Company now owns 15,301 shares of the company’s stock valued at $392,000 after buying an additional 481 shares during the period. Louisiana State Employees Retirement System increased its position in Artivion by 3.1% in the 2nd quarter. Louisiana State Employees Retirement System now owns 19,900 shares of the company’s stock valued at $510,000 after acquiring an additional 600 shares during the period. Intech Investment Management LLC raised its stake in shares of Artivion by 6.6% during the third quarter. Intech Investment Management LLC now owns 10,530 shares of the company’s stock valued at $280,000 after acquiring an additional 653 shares during the last quarter. Quarry LP lifted its holdings in shares of Artivion by 210.8% during the third quarter. Quarry LP now owns 1,209 shares of the company’s stock worth $32,000 after purchasing an additional 820 shares during the period. Finally, nVerses Capital LLC bought a new stake in shares of Artivion in the second quarter worth $28,000. 86.37% of the stock is owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.